Liu Youzhong, Gong Ke, Yuan Songlin, Xu Yong
Youzhong Liu, Department of Thyroid and Breast Surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde 415000, Hunan, China.
Ke Gong, Department of Thyroid and Breast Surgery, Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), Changde 415000, Hunan, China.
Pak J Med Sci. 2025 Mar;41(3):769-773. doi: 10.12669/pjms.41.3.9861.
To explore the chemotherapy effect of albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide on breast cancer and the effects of PCR, ORR and CBR.
This was a retrospective study. During the period from January 2022 to December 2023, ninety patients with breast cancer who were treated in The First People's Hospital of Changde City were included as the research objects. Based on the principle of randomized control, the above patients were divided into the control group (45 cases, treated with pirarubicin and cyclophosphamide) and the observation group (45 cases, treated with albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide) by the random number table. Compared the chemotherapy effect and safety of the two groups.
After treatment, the PCR, ORR and CBR of the observation group were higher than those of the control group, while the levels of CA152, CA125, TPS, HER-2, Ki-67 and EGFR were lower than those of the control group, and the differences were statistically significant (<0.05). The incidence of adverse reactions was 33.33% (15/45), which was slightly higher than that of 28.89% (13/45) in the control group, the difference was not statistically significant (>0.05).
Albumin-bound paclitaxel combined with pirarubicin and cyclophosphamide is a safe regimen that can further enhance the effect of neoadjuvant chemotherapy in the treatment of breast cancer, and it has a certain value for dissemination in the treatment of breast cancer can further enhance the effect of neoadjuvant chemotherapy in patients, which is of certain value for clinical promotion.
探讨白蛋白结合型紫杉醇联合吡柔比星及环磷酰胺对乳腺癌的化疗效果以及对病理完全缓解（PCR）、客观缓解率（ORR）和临床获益率（CBR）的影响。
本研究为回顾性研究。选取2022年1月至2023年12月在常德市第一人民医院接受治疗的90例乳腺癌患者作为研究对象。按照随机对照原则，通过随机数字表将上述患者分为对照组（45例，采用吡柔比星和环磷酰胺治疗）和观察组（45例，采用白蛋白结合型紫杉醇联合吡柔比星和环磷酰胺治疗）。比较两组的化疗效果及安全性。
治疗后，观察组的PCR、ORR和CBR均高于对照组，而CA152、CA125、组织多肽特异性抗原（TPS）、人表皮生长因子受体2（HER-2）、细胞增殖抗原Ki-67和表皮生长因子受体（EGFR）水平低于对照组，差异具有统计学意义（<0.05）。不良反应发生率为33.33%（15/45），略高于对照组的28.89%（13/45），差异无统计学意义（>0.05）。
白蛋白结合型紫杉醇联合吡柔比星及环磷酰胺是一种安全的治疗方案，可进一步提高新辅助化疗在乳腺癌治疗中的效果，对乳腺癌患者新辅助化疗效果的提升具有一定价值，具有一定的临床推广意义。
